Amobarbital

Summary

Amobarbital (CHEMBL267894) is an approved small molecule (ATC N05CA02); indicated across 1 condition including osteoarthritis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N05CA02
• Indications: 1 condition
• Clinical trials: 3
• Chemistry: 226.27 Da · C11H18N2O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL267894
Name	Amobarbital
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	2164
ChEBI	CHEBI:2673
ATC	N05CA02
Molecular formula	C11H18N2O3
Molecular weight	226.27
InChIKey	VIROVYVQCGLCII-UHFFFAOYSA-N

SMILES: CCC1(C(=O)NC(=O)NC1=O)CCC(C)C

IUPAC name: 5-ethyl-5-(3-methylbutyl)-1,3-diazinane-2,4,6-trione

ChEBI definition: A member of the class of barbiturates that is pyrimidine-2,4,6(1H,3H,5H)-trione substituted by a 3-methylbutyl and an ethyl group at position 5. Amobarbital has been shown to exhibit sedative and hypnotic properties.

Also known as: Amobarbital, Amobarbital cii, Amytal, Isomytal, NSC-10815, SID144206419, AMOBARBITAL, amobarbital

Parent form; salt/anhydrous children: CHEMBL2105941

Patent coverage: 5,039 distinct patent families (15,983 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 15,964 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
osteoarthritis	1	MONDO:0005178	MONDO:0005178

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE4	1
PHASE1/PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06385756	PHASE4	NOT_YET_RECRUITING	Effect of Amobarbital Sodium Combined With Low-dose Propofol on Hemodynamics During Induction and Perioperative Adverse Reactions
NCT04589611	PHASE1/PHASE2	COMPLETED	Translating Metabolic Responses to Mechanical Insult Into Early Interventions to Prevent PTOA
NCT06757868	Not specified	RECRUITING	Amobarbital and Cardiopulmonary Bypass

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).